Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 4/20 | 0.71 |
| ▸ | CCKBR | P32239 | 1/20 | 0.71 |
| ▸ | TFPI | P10646 | 1/20 | 0.70 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.69 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.67 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | GCGR | P47871 | 1/20 | 0.64 |
| ▸ | GIPR | P48546 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197505 | 1.00 | GLP1R (0.71) | GLP1RCCKBRTFPIVIPR1VIPR2 | |
| SCHEMBL30504369 | 1.00 | GLP1R (0.71) | GLP1RCCKBRTFPIVIPR1VIPR2 | |
| Acetic Acid SCHEMBL29473498 | 1.00 | GLP1R (0.71) | GLP1RCCKBRTFPIVIPR1VIPR2 | |
| SCHEMBL29403715 | 0.97 | VIPR1 (0.72) | GLP1RCCKBRTFPIVIPR1VIPR2 | |
| SCHEMBL29701273 | 0.97 | TFPI (0.74) | GLP1RCCKBRTFPIVIPR1VIPR2 | |
| SCHEMBL29597420 | 0.97 | TFPI (0.75) | GLP1RCCKBRTFPIVIPR1VIPR2 | |
| SCHEMBL29496440 | 0.96 | VIPR1 (0.71) | GLP1RCCKBRTFPIVIPR1VIPR2 | |
| SCHEMBL29523535 | 0.95 | VIPR1 (0.69) | GLP1RCCKBRTFPIVIPR1VIPR2 | |
| SCHEMBL29382043 | 0.95 | GLP1R (0.80) | GLP1RCCKBRVIPR1VIPR2PTH1R | |
| SCHEMBL29499682 | 0.94 | GLP1R (0.70) | GLP1RCCKBRVIPR1PTH1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2255 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099249-A1 | MODIFIED AND UNMODIFIED PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR USE IN SUBJECTS HAVING INCREASED AMYLOID-BETA AND/OR PHOSPHO-TAU-PROTEIN LOAD AND/OR NEUROINFLAMMATION | PAM THERAGNOSTICS GMBH (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-20260115244-A1 | INJECTABLE NUTRIENT SOLUTION | MARULIS NIKOLAS CARMELO (US) | 2026-04-30 | — | — | US | claimed |
| US-12599651-B2 | Pharmaceuticals and dosing means for human aging reversal | INTERVENE IMMUNE INC. (US) | 2026-04-14 | — | — | US | claimed |
| WO-2026047364-A1 | METHOD FOR TREATMENT OF NEURODEGENERATIVE DISEASES WITH GROWTH HORMONE RELEASING HORMONE AND SYNTHETIC ANALOGS THEREOF | UNIVERSITY OF MIAMI (US) | 2026-03-05 | — | — | WO | claimed |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2026-01-29 | — | — | US | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | claimed |
| WO-2025227129-A2 | DELIVERY VEHICLES COMPRISING PROGLUCAGON DERIVED POLYPEPTIDES AND ANABOLIC POLYPEPTIDES AND USES THEREOF | STARROCK PHARMA LLC (US) | 2025-10-30 | — | — | WO | claimed |
| US-20250325680-A1 | HIGH-PERMEABILITY PROTEIN OR POLYPEPTIDE CONJUGATE AND USE THEREOF | Hangzhou Tito Biotechnology Partnership Enterprise ( Limited Partnership ) (CN) | 2025-10-23 | — | — | US | claimed |
| US-20060002890-A1 | Hydrogel formulations | ASCENDIS PHARMA GMBH (DE) | 2006-01-05 | — | — | US | claimed |
| WO-2005099768-A2 | POLYMERIC PRODRUG WITH A SELF-IMMOLATIVE LINKER | COMPLEX BIOSYSTEMS GMBH (DE) | 2005-10-27 | — | — | WO | claimed |
| EP-1579873-A1 | Polymeric prodrugs | Complex Biosystems GmbH (DE) | 2005-09-28 | — | — | EP | claimed |
| EP-1311239-A4 | ORAL DELIVERY OF PEPTIDE | HYUNDAI PHARM IND CO LTD (KR) | 2005-06-22 | — | — | EP | claimed |
| EP-1525890-A1 | Protein-Proteophore complexes | Complex Biosystems GmbH (DE) | 2005-04-27 | — | — | EP | claimed |
| WO-2005034909-A2 | HYPERBRANCHED POLYMER CONJUGATES VIA NON-ENZYMATIC CLEAVABLE LINKER | COMPLEX BIOSYSTEMS GMBH (DE) | 2005-04-21 | — | — | WO | claimed |
| CN-1479609-A | Oral delivery of peptide | 现代药品工业株式会社 | 2004-03-03 | — | — | CN | claimed |
| EP-1311239-A1 | ORAL DELIVERY OF PEPTIDE | Hyundai Pharm. Ind. Co., Ltd. (KR) | 2003-05-21 | — | — | EP | claimed |
| WO-2002013782-A1 | ORAL DELIVERY OF PEPTIDE | HYUNDAI PHARMACEUTICAL IND. CO., LTD (KR) | 2002-02-21 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |